EDSA Stock Rallied Over 50% Today: What’s Ahead For The Small-Cap Biotech?

• The CEO will present findings from Edesa’s late-stage study of EB05, being evaluated as a treatment for Acute Respiratory Distress Syndrome (ARDS), at the conference.
• The company expects to start recruiting patients for its mid-stage vitiligo trial starting in mid-2026.
• According to data from  Koyfin, both analysts covering EDSA rate it ‘Buy.’

Shares of Edesa Biotech (EDSA) rallied 54% higher on Monday, closing at a new 52-week high of $11.17.  

The rally comes ahead of the company CEO’s upcoming presentation at the ATS 2026 Respiratory Innovation Summit (RIS), organized by the American Thoracic Society (ATS), on May 15. The CEO will present findings from Edesa’s late-stage study of EB05, being evaluated as a treatment for Acute Respiratory Distress Syndrome (ARDS), at the conference.

In February, Edesa reported positive late-stage trial results for EB05. The company said that the drug demonstrated statistically significant reductions in 28-day mortality across a broader patient population in the trial.  

Remaining Pipeline

Edesa is a biopharmaceutical company developing treatments for inflammatory and immune-related diseases. The company’s pipeline includes EB06, being developed as a therapy for vitiligo, and EB01 for the treatment of moderate-to-severe chronic Allergic Contact Dermatitis.

Last month, the company said that it expects to start recruiting patients for its mid-stage vitiligo trial starting in mid-2026. The trial is aimed at evaluating the safety and efficacy of EB06 compared to adults in adults with with generalized vitiligo.

Analyst Takeaway

According to data from  Koyfin, both analysts covering EDSA rate it ‘Buy.’

The average 12-month price target on the stock is $11, representing a potential downside of about 2%.

How Did Retail Traders React?

On Stocktwits, retail sentiment around EDSA stock jumped from ‘bearish’ to ‘bullish’ territory while message volume rose from ‘high’ to ‘extremely high’ levels.

A Stocktwits user speculated a buyout price for the company.

EDSA stock has gained 365% over the past 12 months. 

Read More: TSLA Overvalued? Fund Manager Demands Math on $3,000 Bull Targets

For updates and corrections, email newsroom[at]stocktwits[dot]com.